Global Amyotrophic Lateral Sclerosis Market 2014-2018
|出版商||TechNavio (Infiniti Research Ltd.)||商品編碼||294972|
|出版日期||內容資訊||英文 46 Pages
|全球肌肉萎縮性側索硬化症(俗稱漸凍人)(ALS)市場 Global Amyotrophic Lateral Sclerosis Market 2014-2018|
|出版日期: 2014年01月17日||內容資訊: 英文 46 Pages||
TechNavio's analysts forecast the Global Amyotrophic Lateral Sclerosis Drugs Market to grow at a CAGR of 5.39 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing global aging population. The Global Amyotrophic Lateral Sclerosis Drugs Market has also been witnessing the increasing awareness of ALS drugs. However, the patent expiry of Rilutek could pose a challenge to the growth of this market.
TechNavio's report, the Global Amyotrophic Lateral Sclerosis Drugs market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers Americas, EMEA and APAC regions; it also covers the Global Amyotrophic Lateral Sclerosis Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors dominating this space include Covis Pharmaceutical Inc., Eisai Co. Ltd., GlaxoSmithKline plc, and Mitsubishi Tanabe Pharma Corp.
Other vendors mentioned in the report are Amorfix Life Sciences Ltd., BrainStrom Cell Therapeutics Inc., Newron Pharmaceuticals S.p.A, Neuraltus Pharmaceuticals Inc., Nutra Pharma Corp., Oxford BioMedica plc, Pharnext SAS, and Q-Therapeutics Inc.
You can request one free hour of our analyst's time when you purchase this market report. Details provided within the report.